Advertisement

Drugs

, Volume 78, Issue 9, pp 913–928 | Cite as

CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine

  • Kasra Maasumi
  • Rebecca L. Michael
  • Alan M. Rapoport
Review Article

Abstract

Migraine is a highly prevalent, complex neurological disorder. The burden of disease and the direct/indirect annual costs are enormous. Thus far, treatment options have been inadequate and mostly based on trial and error, leaving a significant unmet need for effective therapies. While the underlying pathophysiology of migraine is incompletely understood, blocking the calcitonin gene-related peptide (CGRP) using monoclonal antibodies targeting CGRP or its receptor and small molecule CGRP receptor antagonists (gepants) have emerged as a promising therapeutic opportunity for the management of migraine. In this review, we discuss new concepts in the pathophysiology of migraine and the role of CGRP, the current guidelines for treating migraine preventively, the medications that are being used, and their limitations. We then discuss small molecule CGRP receptor antagonists, monoclonal antibodies to CGRP ligand and receptor, as well as the detailed results of Phase II and III trials involving these novel treatments. We conclude with a discussion of the implications of blocking CGRP and its receptor.

Notes

Compliance with Ethical Standards

Conflict of interest

Dr. Rapoport is a speaker for Amgen, Avanir, Depomed, Electrocore, Promius, and Teva. He is also an advisor for Amgen, Autonomic Technologies, Promius, Impax, Satsuma, Teva and Zosano. Dr. Maasumi is an advisor/speaker for Amgen and Autonomic Technologies. Dr. Michael has no conflict of interest.

References

  1. 1.
    Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(Suppl 1):S3–s13.CrossRefPubMedGoogle Scholar
  3. 3.
    Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.Google Scholar
  4. 4.
    Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553–622.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62:131–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Uddman R, Goadsby PJ, Jansen I, Edvinsson L. PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab. 1993;13:291–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Uddman R, Edvinsson L. Neuropeptides in the cerebral circulation. Cerebrovasc Brain Metab Rev. 1989;1:230–52.PubMedGoogle Scholar
  10. 10.
    Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R. Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. Neurosci Lett. 1983;43:79–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci. 1985;8:126–31.CrossRefGoogle Scholar
  12. 12.
    Edvinsson L, Brodin E, Jansen I, Uddman R. Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regul Pept. 1988;20:181–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia. 1995;15:272–6.CrossRefPubMedGoogle Scholar
  14. 14.
    May A, Goadsby PJ. Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs. 2001;10:673–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Sundrum T, Walker CS. Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol. 2017.  https://doi.org/10.1111/bph.14053.PubMedCrossRefGoogle Scholar
  16. 16.
    Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132:16–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992;37:287–303.PubMedGoogle Scholar
  18. 18.
    Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Walker CS, Hay DL. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol. 2013;170:1293–307.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507:1277–99.CrossRefPubMedGoogle Scholar
  22. 22.
    Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011;12:112.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169:683–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14:1289–303.CrossRefPubMedGoogle Scholar
  25. 25.
    McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA. 1986;83:5731–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, Trequattrini A, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15:384–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19:3423–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Edvinsson L, Ekman R, Goadsby PJ. Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia. 2010;30:761–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–82.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Sci Transl Med. 2015;7:308ra157.CrossRefPubMedGoogle Scholar
  34. 34.
    Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18:34.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21:649–78.CrossRefPubMedGoogle Scholar
  37. 37.
    Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci. 2011;46:333–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Recober A, Russo AF. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007;10:566–74.PubMedGoogle Scholar
  39. 39.
    Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol. 2012;14:50–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Joshi S, Rapoport AM. Diclofenac potassium for oral solution (CAMBIA((R))) in the acute management of a migraine attack: clinical evidence and practical experience. Ther Adv Neurol Disord. 2017;10:217–26.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455–64.CrossRefPubMedGoogle Scholar
  43. 43.
    Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled Phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled Phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470–85.CrossRefPubMedGoogle Scholar
  47. 47.
    Edvinsson L. Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev. 2005;11:69–76.CrossRefPubMedGoogle Scholar
  48. 48.
    Silberstein S, Lenz R, Xu C. Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 2015;55:1171–82.CrossRefPubMedGoogle Scholar
  49. 49.
    Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–32.CrossRefPubMedGoogle Scholar
  50. 50.
    Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–22.CrossRefPubMedGoogle Scholar
  51. 51.
    Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79:886–95.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Neurol. 2016;15:382–90.CrossRefPubMedGoogle Scholar
  53. 53.
    Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017;89:1237–43.CrossRefPubMedGoogle Scholar
  54. 54.
    Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled Phase 2 trial. Lancet Neurol. 2017;16:425–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a Phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92.CrossRefPubMedGoogle Scholar
  56. 56.
    Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, ALDs Investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory Phase 2 trial. Lancet Neurol. 2014;13:1100–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, Phase 2b study. Lancet Neurol. 2015;14:1081–90.CrossRefPubMedGoogle Scholar
  58. 58.
    Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87:41–8.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017;57:1375–84.CrossRefPubMedGoogle Scholar
  60. 60.
    Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–37.CrossRefPubMedGoogle Scholar
  61. 61.
    Malone CD, Bhowmick A, Wachholtz AB. Migraine: treatments, comorbidities, and quality of life, in the USA. J Pain Res. 2015;8:537–47.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2015;17:28.CrossRefPubMedGoogle Scholar
  63. 63.
    Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6:534–47.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30:272–80.CrossRefPubMedGoogle Scholar
  65. 65.
    Krishna M, Nadler SG. Immunogenicity to biotherapeutics—the role of anti-drug immune complexes. Front Immunol. 2016;7:21.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Kasra Maasumi
    • 1
  • Rebecca L. Michael
    • 1
  • Alan M. Rapoport
    • 2
  1. 1.Department of NeurologyUniversity of CaliforniaSan FranciscoUSA
  2. 2.Department of NeurologyUniversity of CaliforniaLos AngelesUSA

Personalised recommendations